A5082846907- Hemoglobinopathies and Related Disorders
- Long-Term Effects of COVID-19
- Iron Metabolism and Disorders
- COVID-19 Clinical Research Studies
- COVID-19 and Mental Health
- SARS-CoV-2 and COVID-19 Research
- Schizophrenia research and treatment
- Patient Satisfaction in Healthcare
- Folate and B Vitamins Research
- Pharmacological Effects and Toxicity Studies
- Complement system in diseases
- Psychosomatic Disorders and Their Treatments
- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Health and Well-being Studies
- Healthcare cost, quality, practices
- Intensive Care Unit Cognitive Disorders
- Mental Health and Psychiatry
- Retinal Imaging and Analysis
- Retinal Diseases and Treatments
- Cancer Treatment and Pharmacology
- SARS-CoV-2 detection and testing
- Musculoskeletal pain and rehabilitation
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Nonmelanoma Skin Cancer Studies
Regeneron (United States)
2020-2025
Arizona Liver Health
2020
Roche (Switzerland)
2015
Adelphi Group (United Kingdom)
2006-2012
East Cheshire NHS Trust
2012
Mapi Research Trust
2008-2010
Adelphi Laboratory Center
2010
Hôpital Pontchaillou
2010
Inserm
2010
Novartis (United States)
2007
BackgroundRecent data suggest that complications and death from coronavirus disease 2019 (Covid-19) may be related to high viral loads.MethodsIn this ongoing, double-blind, phase 1–3 trial involving nonhospitalized patients with Covid-19, we investigated two fully human, neutralizing monoclonal antibodies against severe acute respiratory syndrome 2 (SARS-CoV-2) spike protein, used in a combined cocktail (REGN-COV2) reduce the risk of emergence treatment-resistant mutant virus. Patients were...
In the phase 1-2 portion of an adaptive trial, REGEN-COV, a combination monoclonal antibodies casirivimab and imdevimab, reduced viral load number medical visits in patients with coronavirus disease 2019 (Covid-19). REGEN-COV has activity vitro against current severe acute respiratory syndrome 2 (SARS-CoV-2) variants concern. 3 we randomly assigned outpatients Covid-19 risk factors for to receive various doses intravenous or placebo. Patients were followed through day 29. A prespecified...
This paper reports a study examining patients' satisfaction with and subjective experiences of taking antipsychotic medication.Treatment is increasingly recognized as an important indication the quality health care, providing reference point against which clinicians can gauge their practice. To date published literature has been limited, no clear whether patients are indeed satisfied regimens, what treatment are.A cross-sectional survey was carried out receiving secondary care about...
Objectives: Iron chelation treatment (ICT) in β-thalassemia major (β-TM) patients undergoing blood transfusions can cause low satisfaction, compliance, with possible negative consequences on success, patients' wellbeing, and costs. The purpose was to estimate the societal burden attributable β-TM terms of direct indirect costs, health-related quality-of-life (HRQoL), satisfaction compliance ICT ICT.Research design methods: naturalistic, multicenter, longitudinal...
Treatment of iron overload using deferoxamine (DFO) is associated with significant deficits in patients' health-related quality life (HRQOL) and low treatment satisfaction. The current article presents patient-reported HRQOL, satisfaction, adherence, persistence data from β-thalassemia (n = 274) myelodysplastic syndrome (MDS) patients 168) participating the Evaluation Patients' Iron Chelation Exjade (EPIC) study (NCT00171821); a large-scale 1-year, phase IIIb investigating efficacy safety...
ABSTRACT Background REGEN-COV antibody cocktail (casirivimab with imdevimab) rapidly reduced viral load and decreased medically-attended visits in the phase 1/2 portion of this trial; REGEN-COV, retains activity vitro against emerging SARS-CoV-2 variants concern. Methods The 3 adaptive, randomized, master protocol, included 4,057 Covid-19 outpatients one or more risk factors for severe disease. Patients were randomized to a single treatment intravenous placebo, various doses followed 28...
The prevalence and burden of atopic dermatitis (AD) are disproportionately high in individuals with skin colour (SOC). Previous research shows that risk for xerosis and/or dyspigmentation is heightened this population may be more bothersome. However, there no patient-reported instruments developed specifically these disease sequelae patients SOC. To develop perform content validation outcome (PRO) questionnaires to assess AD-related A targeted literature review was conducted understand...
There is increasing evidence demonstrating the value of transfusions in sickle cell disease (SCD). However, resultant iron overload can be life threatening if untreated. Chelation therapy with deferoxamine requires parenteral infusions that negatively impact quality and adherence to treatment.As part a phase II trial, SCD patient-reported outcomes were evaluated. One hundred ninety-five patients randomized (2:1) receive oral deferasirox (5-30 mg/kg/day) or (20-50 mg/kg, 5 days per week); 121...
BACKGROUND: Hereditary hemochromatosis (HH) is a genetic disorder resulting in increased accumulation of dietary iron. It associated with various clinical complications such as liver cirrhosis and diabetes. The aim this study was to explore patients’ experiences living HH, the diagnosis process, phlebotomy treatment. STUDY DESIGN AND METHODS: An online survey developed completed by total 210 HH patients across United States (n = 70), France 50), Ireland 40), Kingdom 50). RESULTS: Of...
Patient-reported outcomes of once-daily oral deferasirox (Exjade) in iron-overloaded patients with beta-thalassemia not achieving successful chelation prior deferoxamine and/or deferiprone were investigated a prospective, open-label, 1-year, multicenter study the Middle East (ESCALATOR). The initial dose was 20 mg/kg/day, subsequent adjustments. At baseline and end (EOS), (n = 237) completed 5-point rating scale for treatment satisfaction convenience, recorded time lost to treatment. EOS,...
Objectives There is little in-depth qualitative evidence of how symptoms manifest themselves in outpatients with COVID-19 and these turn impact outpatients’ daily lives. The objective the study was therefore to explore experience qualitatively, concerning symptomatic its subsequent on life. Setting Qualitative research comprising virtual in-depth, open-ended interviews clinicians. Participants Thirty US adult patients were interviewed within 21 days diagnosis. Patients 60% female 87% white,...
BACKGROUND: Patients requiring chronic blood transfusions are at risk for iron overload, which, if not treated by chelation therapy (ICT), can create serious organ damage and reduce life expectancy. Current ICT requires burdensome 8‐ to 12‐hour infusions five seven times per week. STUDY DESIGN AND METHODS: A naturalistic study of the burden infused was conducted in four US centers. Data from initial most recent years were collected medical charts consenting thalassemia (n = 40) sickle cell...
ABSTRACT Background Continued SARS-CoV-2 infections and COVID-19-related hospitalizations highlight the need for effective anti-viral treatments in outpatient setting. In a descriptive interim analysis of phase 1/2 portion double-blind 1/2/3 trial COVID-19 outpatients conducted between June 16, 2020 September 4, 2020, REGEN-COV ® (casirivimab plus imdevimab) antibody combination reduced viral load versus placebo. Methods This final comprises 799 outpatients, including 275 from previous...
Background. Satisfaction with antipsychotic medication is an important outcome variable. To date, there a lack of well-established measure to quantify patient satisfaction psychiatric medication. This paper describes the development, dimensionality, reliability and validity Antipsychotic Medication (SWAM) scale.Method. Clinical academic experts devised 33-item Likert scale questionnaire. Following pilot study in sample 69 people schizophrenia, 315 schizophrenia on caseload local mental...
At the onset of COVID-19 pandemic, there was limited understanding symptom experience and disease progression. We developed validated a fit-for-purpose disease-specific instrument to assess symptoms in patients with inform endpoints an interventional trial for non-hospitalized patients.The initial drafting 23-item Symptoms Evolution (SE-C19) Instrument based on Centers Disease Control Prevention list available published literature specific as Spring 2020. The measurement principles outlined...
Severe, protracted symptoms are associated with poor outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In a placebo-controlled study of casirivimab and imdevimab (CAS + IMD) persons at high risk disease 2019 (COVID-19; n = 3816), evolution individual was assessed for resolution patterns across factors, baseline SARS-CoV-2-specific antibody responses against S1 N domains. CAS IMD versus placebo provided statistically significant 17/23 symptoms, greater...